Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Fineline Cube Jan 20, 2026
Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Fineline Cube Jan 20, 2026
Company Drug

Hinova Pharmaceuticals’ HP537 Receives FDA Approval for Phase I/II Clinical Trial in Hematologic Malignancies

Fineline Cube Jul 8, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...

Company Drug

Easton Pharmaceutical Receives NMPA Approval for Generic Oxcarbazepine

Fineline Cube Jul 8, 2024

Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...

Company Drug

Amoytop Biotech’s Peginterferon α-2b Receives NMPA Approval for Primary Thrombocytosis Clinical Trial

Fineline Cube Jul 8, 2024

Amoytop Biotech Co. Ltd (SHA: 688278), based in Xiamen, has announced that it has received...

Company Drug

Daiichi Sanky’s Mirogabalin Gets Green Light from China for Diabetic Neuropathic Pain

Fineline Cube Jul 8, 2024

Daiichi Sanky (TYO: 4568), a pharmaceutical company based in Japan, has announced that it has...

Company Drug

Antengene’s Xpovio Secures NMPA Approval for R/R Diffuse Large B-Cell Lymphoma

Fineline Cube Jul 8, 2024

Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...

Company Drug

Sirnaomics’ STP122G Achieves Phase I Milestone with Positive Interim Data for Anticoagulation Treatment

Fineline Cube Jul 8, 2024

Sirnaomics Ltd (HKG: 2257) has announced the completion of the Phase I second sequence for...

Company Deals

Kindstar Global and MGI Tech Co., Ltd. Form Partnership to Establish Multi-Omics Service Center in China

Fineline Cube Jul 8, 2024

Kindstar Global (HKG: 9960), a biopharmaceutical company based in China, has announced a strategic partnership...

Company Legal / IP

Pharmaceutical Giants Face UK Industry Code Breach Allegations, Including Novartis and Pfizer

Fineline Cube Jul 8, 2024

Several multinational pharmaceutical corporations have been reprimanded for violating the UK’s Prescription Medicines Code, a...

Company Drug

Roche’s Tiragolumab Misses Primary Endpoints in NSCLC Trial, Study Halted

Fineline Cube Jul 8, 2024

Roche (SWX: ROG; SWX: RO; OTCMKTS: RHHBY), the Swiss pharmaceutical giant, has announced that a...

Company Drug

Medigene AG Secures Chinese Patent for TCR-T Therapy Targeting NY-ESO-1 and LAGE 1a

Fineline Cube Jul 8, 2024

Medigene AG (ETR: MDG1), a biopharmaceutical company based in Germany, has announced that it has...

Company

MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth

Fineline Cube Jul 5, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai...

Company Deals

Singlera Genomics Secures Over RMB 100 Million in Strategic Financing to Boost R&D and Commercialization

Fineline Cube Jul 5, 2024

Singlera Genomics Inc., a genetic testing and molecular diagnostics company with operations in San Diego,...

Company Drug

Doma Biopharmaceutical’s Bispecific ADC DM001 Receives FDA Clearance for Clinical Trial

Fineline Cube Jul 5, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-9813 IPF Clinical Trial

Fineline Cube Jul 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

Luye Pharma’s Oxycodone/Naloxone Product Receives NMPA Approval for Severe Pain Management

Fineline Cube Jul 5, 2024

Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it...

Company Drug R&D

Semaglutide Use Linked to Rare Eye Condition NAION in New Study

Fineline Cube Jul 5, 2024

A recent study has identified a potential link between the use of GLP-1-targeted diabetes and...

Company Drug

J&J’s Rybrevant Earns First-Line NSCLC Approval in Canada, a Milestone for EGFR Exon 20 Patients

Fineline Cube Jul 5, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that Rybrevant (amivantamab) has received its first...

Company Drug

Sanofi’s RSV Preventative Therapy Beyfortus Launches in China

Fineline Cube Jul 4, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus...

Company Deals

Genertec and CTHG Fund Invest in Neusoft Medical Systems to Boost Medical Imaging

Fineline Cube Jul 4, 2024

China General Technology (Group) Holding Co Ltd, commonly referred to as Genertec, has announced plans...

Company Deals

Guangzhou Pluslife Partners with Gates Foundation to Combat STIs in Low-Income Countries

Fineline Cube Jul 4, 2024

Guangzhou Pluslife Technology Co., Ltd, a specialist in Point-Of-Care Testing (POCT) based in China, has...

Posts pagination

1 … 280 281 282 … 611

Recent updates

  • Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
  • Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
  • AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
  • Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
  • Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.